Source: Lixte Biotechnology Holdings, Inc.
EAST SETAUKET, NY, Feb. 09, 2018 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT) noted that investigators at the Terry Fox Laboratory, British Columbia Cancer Agency, Vancouver, British Columbia, Canada, reported on February 7, 2018 (Lai et al., Sci. Transl. Med.10, eaan8735 (2018)) that in animal models Lixte’s protein phosphatase 2A (PP2A) inhibitors overcome resistance of chronic myelogenous leukemia (CML) cells to standard treatment.
Dr. John S. Kovach, CEO of Lixte, said "The vast majority of CML cells are killed by drugs called tyrosine kinase inhibitors (TKI), the prototype of which is imatinib (Gleevec), considered the first truly targeted form of chemotherapy. Imatinib and subsequent variants were a great advance in turning CML from a fatal to a controllable illness. Almost without exception, however, from the onset of the disease some CML cells are resistant to TKI treatment so that continuous therapy is required and in some patients the number of TKI resistant cells accelerates out of control. The persistence and progression of CML despite TKI treatment is believed to arise from a niche of intrinsically resistant leukemia stem cells. The Terry Fox investigators found inhibition of PP2A with LB-100 or LB-102 preferentially sensitizes these resistant CML cells to killing by TKI compared to normal bone marrow stem cells. If these results can be replicated in the clinic, LB-100 and analogs may further improve the effectiveness of CML therapy.”
About Lixte Biotechnology Holdings, Inc.
Lixte is a biotech company that identifies enzyme targets associated with serious common diseases and then designs novel compounds to attack those targets. Lixte's product pipeline encompasses two major categories of compounds at various stages of pre-clinical and clinical development that the Company believes have broad therapeutic potential not only for cancer but also for other debilitating and life-threatening diseases.
This announcement contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. For example, statements regarding the Company's financial position, business strategy and other plans and objectives for future operations, and assumptions and predictions about future product demand, supply, manufacturing, costs, marketing and pricing factors are all forward-looking statements. These statements are generally accompanied by words such as "intend," anticipate," "believe," "estimate," "potential(ly)," "continue," "forecast," "predict," "plan," "may," "will," "could," "would," "should," "expect" or the negative of such terms or other comparable terminology. The Company believes that the assumptions and expectations reflected in such forward-looking statements are reasonable, based on information available to it on the date hereof, but the Company cannot provide assurances that these assumptions and expectations will prove to have been correct or that the Company will take any action that the Company may presently be planning. However, these forward-looking statements are inherently subject to known and unknown risks and uncertainties. Actual results or experience may differ materially from those expected or anticipated in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, regulatory policies, available cash, research results, competition from other similar businesses, and market and general economic factors. This discussion should be read in conjunction with the Company's filings with the United States Securities and Exchange Commission at http://www.sec.gov/edgar.shtml.
Additional information on the Company is available at www.lixte.com.
Contact info: email@example.com (631) 830-7092